5,718 Shares in Cencora, Inc. (NYSE:COR) Acquired by TFR Capital LLC.

TFR Capital LLC. acquired a new position in shares of Cencora, Inc. (NYSE:COR) in the 1st quarter, according to its most recent 13F filing with the SEC. The fund acquired 5,718 shares of the company’s stock, valued at approximately $1,590,000.

Other institutional investors have also recently modified their holdings of the company. Schear Investment Advisers LLC raised its holdings in Cencora by 2.8% in the 1st quarter. Schear Investment Advisers LLC now owns 6,417 shares of the company’s stock valued at $1,785,000 after acquiring an additional 176 shares during the last quarter. New York State Common Retirement Fund raised its holdings in Cencora by 3.7% in the 1st quarter. New York State Common Retirement Fund now owns 116,494 shares of the company’s stock valued at $32,396,000 after acquiring an additional 4,136 shares during the last quarter. Arizona State Retirement System raised its holdings in Cencora by 0.9% in the 1st quarter. Arizona State Retirement System now owns 51,049 shares of the company’s stock valued at $14,196,000 after acquiring an additional 453 shares during the last quarter. Kathmere Capital Management LLC raised its holdings in Cencora by 9.8% in the 1st quarter. Kathmere Capital Management LLC now owns 2,295 shares of the company’s stock valued at $638,000 after acquiring an additional 204 shares during the last quarter. Finally, Ballentine Partners LLC raised its holdings in Cencora by 0.7% in the 1st quarter. Ballentine Partners LLC now owns 8,943 shares of the company’s stock valued at $2,487,000 after acquiring an additional 63 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Trading Down 0.8%

COR stock opened at $295.07 on Friday. The company has a market cap of $57.19 billion, a price-to-earnings ratio of 34.23, a PEG ratio of 1.46 and a beta of 0.57. The company has a quick ratio of 0.52, a current ratio of 0.87 and a debt-to-equity ratio of 6.01. The business has a fifty day simple moving average of $291.91 and a 200-day simple moving average of $269.98. Cencora, Inc. has a 52 week low of $218.65 and a 52 week high of $309.35.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.07 by $0.35. Cencora had a return on equity of 344.71% and a net margin of 0.55%. The firm had revenue of $75.50 billion during the quarter, compared to the consensus estimate of $75.41 billion. During the same period in the prior year, the firm earned $3.80 EPS. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. On average, equities research analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Investors of record on Friday, May 16th were issued a $0.55 dividend. The ex-dividend date of this dividend was Friday, May 16th. This represents a $2.20 annualized dividend and a yield of 0.75%. Cencora’s dividend payout ratio is currently 25.52%.

Wall Street Analysts Forecast Growth

COR has been the subject of several analyst reports. Jefferies Financial Group boosted their price target on Cencora from $275.00 to $300.00 and gave the company a “hold” rating in a report on Monday, June 30th. Morgan Stanley set a $288.00 price target on Cencora in a report on Tuesday, April 15th. Robert W. Baird boosted their price target on Cencora from $314.00 to $350.00 and gave the company an “outperform” rating in a report on Thursday, May 8th. Citigroup boosted their price target on Cencora from $330.00 to $355.00 and gave the company a “buy” rating in a report on Thursday, May 8th. Finally, Wells Fargo & Company upgraded Cencora from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $274.00 to $337.00 in a report on Tuesday, June 3rd. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and an average price target of $306.33.

Insider Buying and Selling at Cencora

In related news, Chairman Steven H. Collis sold 14,579 shares of the stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $292.62, for a total value of $4,266,106.98. Following the completion of the sale, the chairman directly owned 311,913 shares in the company, valued at approximately $91,271,982.06. This represents a 4.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Robert P. Mauch sold 4,969 shares of the stock in a transaction on Monday, April 21st. The shares were sold at an average price of $289.33, for a total value of $1,437,680.77. Following the completion of the sale, the chief executive officer owned 47,582 shares of the company’s stock, valued at approximately $13,766,900.06. This represents a 9.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 34,127 shares of company stock valued at $9,812,296. 10.80% of the stock is owned by insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.